Worth reading
30Immaterial
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 12 May 2026Incoming appointee
5 itemsScheduled Appointment Date25 June 2026 (the appointment of the director candidates is scheduled to be formally decided subject to approval at the 39th Ordinary General Meeting of Shareholders scheduled for the same date and a resolution of the Board of Directors after that meeting)
Yasuda Tadashi (安田 忠史)
Previous positionSame as above
New positionPresident and Representative Director; President Executive Officer
Fukui Takashi (福井 崇史)
Previous positionDirector, Executive Vice President, Head of Genomics Business Office
New positionDirector, Executive Vice President, Head of Clinical Business Office, Head of Genomics Business Office
Ōma Hisayuki (大馬 久幸)
Previous positionSame as above
New positionDirector, Executive Officer, Head of Pharma Business Office
Kuroda Shuhei (黒田 修平)
Previous positionDirector, Executive Officer, Head of IR Office, Head of Administration Office, Deputy Head of ICT Business Office
New positionDirector, Executive Officer, Head of Corporate Planning Office, Head of Administration Office, Deputy Head of ICT Business Office
Shimada Kei (島田 圭)
Previous positionSame as above
New positionDirector, Executive Officer, Head of ICT Business Office, Deputy Head of Genomics Business Office
Departing officer
4 itemsDate of departure25 June 2026
Kawada Yoichi (河田 與一)Next role stated
Former PositionDirector, Senior Executive Officer, Head of Clinical Business Office
New positionRetirement (scheduled to become Chairman of the Board of Directors of 株式会社ファルコバイオシステムズ effective 19 June 2026)
Gōda Tetsuo (郷田 哲夫)Next role stated
Former PositionDirector, Head of Corporate Planning Office
New positionExecutive Officer, Head of the President’s Office
Abe Osamu (阿部 治)Next role stated
Former PositionExecutive Officer, Deputy Head of Pharma Business Office
New positionRetirement (scheduled to become Representative Director of 株式会社ファルコファーマシーズ and Representative Director of チューリップ調剤株式会社 effective 19 June 2026)
Sato Kayoko (佐藤佳代子)Next role stated
Former PositionExecutive Officer, Deputy Head of Pharma Business Office
New positionRetirement (scheduled to become Senior Managing Director of 株式会社アテスト effective 19 June 2026)
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
Kawada Yoichi (河田 與一) will retire as a director of the company. Gōda Tetsuo (郷田 哲夫) will remain with the company as an Executive Officer. No new position at the company is stated for Abe Osamu (阿部 治) or Sato Kayoko (佐藤佳代子).
Shareholders’ meeting approvalYes. Approval of the proposal concerning the director candidates at the 39th Ordinary General Meeting of Shareholders scheduled for 25 June 2026, followed by a resolution of the Board of Directors after that meeting.
Details of organizational changes
Effective 25 June 2026, a President's Office will be established as a department responsible for special assignments. Gōda Tetsuo (郷田哲夫) will be appointed Head of the President's Office.
| Item | Details |
|---|---|
| Resolution date | 12 May 2026 |
| Scheduled Appointment Date | 25 June 2026 (the appointment of the director candidates is scheduled to be formally decided subject to approval at the 39th Ordinary General Meeting of Shareholders scheduled for the same date and a resolution of the Board of Directors after that meeting) |
| Date of departure | 25 June 2026 |
| Name of appointee | Yasuda Tadashi (安田 忠史), Fukui Takashi (福井 崇史), Ōma Hisayuki (大馬 久幸), Kuroda Shuhei (黒田 修平), Shimada Kei (島田 圭) |
| Appointee's new position | President and Representative Director; President Executive Officer, Director, Executive Vice President, Head of Clinical Business Office, Head of Genomics Business Office, Director, Executive Officer, Head of Pharma Business Office, Director, Executive Officer, Head of Corporate Planning Office, Head of Administration Office, Deputy Head of ICT Business Office, Director, Executive Officer, Head of ICT Business Office, Deputy Head of Genomics Business Office |
| Appointee's previous position | Same as above, Director, Executive Vice President, Head of Genomics Business Office, Same as above, Director, Executive Officer, Head of IR Office, Head of Administration Office, Deputy Head of ICT Business Office, Same as above |
| Name of departing officer | Kawada Yoichi (河田 與一), Gōda Tetsuo (郷田 哲夫), Abe Osamu (阿部 治), Sato Kayoko (佐藤佳代子) |
| Former position of departing officer | Director, Senior Executive Officer, Head of Clinical Business Office, Director, Head of Corporate Planning Office, Executive Officer, Deputy Head of Pharma Business Office, Executive Officer, Deputy Head of Pharma Business Office |
| New position of departing officer | Retirement (scheduled to become Chairman of the Board of Directors of 株式会社ファルコバイオシステムズ effective 19 June 2026), Executive Officer, Head of the President’s Office, Retirement (scheduled to become Representative Director of 株式会社ファルコファーマシーズ and Representative Director of チューリップ調剤株式会社 effective 19 June 2026), Retirement (scheduled to become Senior Managing Director of 株式会社アテスト effective 19 June 2026) |
| Whether the incumbent will remain in office | Kawada Yoichi (河田 與一) will retire as a director of the company. Gōda Tetsuo (郷田 哲夫) will remain with the company as an Executive Officer. No new position at the company is stated for Abe Osamu (阿部 治) or Sato Kayoko (佐藤佳代子). |
| Details of organizational changes | Effective 25 June 2026, a President's Office will be established as a department responsible for special assignments. Gōda Tetsuo (郷田哲夫) will be appointed Head of the President's Office. |
| Subject to Approval by the General Meeting of Shareholders | Yes. Approval of the proposal concerning the director candidates at the 39th Ordinary General Meeting of Shareholders scheduled for 25 June 2026, followed by a resolution of the Board of Directors after that meeting. |
Items this document does not state (9)
Appointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The changes in directors are scheduled to be formally decided following approval at the Ordinary General Meeting of Shareholders scheduled for 25 June 2026 and a resolution of the Board of Directors after that meeting. With regard to the organizational changes, the company will establish a President's Office as a department responsible for special assignments. No reason for the personnel changes themselves is stated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.